soman has been researched along with Neurodegenerative Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuruba, R; Reddy, DS; Reddy, SD; Sridhar, V; Wu, X | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP | 1 |
2 other study(ies) available for soman and Neurodegenerative Diseases
| Article | Year |
|---|---|
Magnetic resonance imaging analysis of long-term neuropathology after exposure to the nerve agent soman: correlation with histopathology and neurological dysfunction.
Topics: Animals; Hippocampus; Interneurons; Magnetic Resonance Imaging; Male; Memory Disorders; Nerve Agents; Neurodegenerative Diseases; Neuroimaging; Rats; Rats, Sprague-Dawley; Soman; Time Factors | 2020 |
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Isoquinolines; Neurodegenerative Diseases; Neurons; Rats; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles | 2011 |